A Systems Framework for Quantifying Programmability and Persistence Across Mammalian Cell Types

This review synthesizes data from over 50 mammalian cell populations to introduce a unified Programmability & Persistence Score (PPS) and Pareto frontier analysis, enabling the quantitative selection of optimal cell types for diverse translational applications by balancing lifespan, engraftment, immunogenicity, and stress resilience.

The Gist

Imagine you are a master architect trying to build a living, breathing city inside the human body. You need to choose the right "construction workers" (cells) for different jobs. Some jobs need workers who can stay on the site for 50 years (like building a new heart valve), while others need workers who are great at putting out fires quickly but don't need to stay long (like cleaning up an infection).

For a long time, scientists picking these cells were like architects guessing in the dark. They didn't have a standard rating system to compare a "neutrophil" (a short-lived immune cell) against a "stem cell" or a "engineered T-cell." They just guessed based on experience.

This paper introduces a universal "Cell Report Card" called the Programmability & Persistence Score (PPS). It's a way to grade every type of mammalian cell from 0 to 20, helping doctors and scientists pick the perfect worker for the job.

Here is how the system works, broken down into simple concepts:

1. The Four Grades on the Report Card

Just like a student gets grades in Math, Reading, Science, and Art, every cell gets a score in four specific areas:

• Stamina (Intrinsic Stability): How long does this cell naturally live? Is it a "one-night stand" (like a neutrophil that dies in hours) or a "marathon runner" (like a neuron that lives a lifetime)?
• Loyalty (Post-Transplant Persistence): If we move this cell to a new place (transplant), will it stick around and keep working, or will it run away or die immediately?
• Diplomacy (Immunogenicity): How friendly is this cell to the body's security system (the immune system)?
  • High Diplomacy: The body accepts it easily (like a VIP guest).
  • Low Diplomacy: The body sees it as an invader and attacks it (like a burglar).
• Toughness (Chemical Resilience): Can this cell survive the harsh conditions of being grown in a lab, frozen, thawed, or exposed to drugs? Or is it as fragile as a soap bubble?

2. The "Score" (0 to 20)

The paper adds these four grades together to get a final PPS Score.

• Low Score (0–9): These are the "Special Forces" or "Firefighters." They are great for short, intense tasks (like killing a virus quickly) but they burn out fast or get rejected easily. Example: Neutrophils and Enterocytes (gut lining cells).
• High Score (15–18): These are the "Master Builders." They are tough, long-lived, and don't get rejected. They are perfect for rebuilding organs or long-term therapies. Example: Hypoimmune iPSCs (super-engineered stem cells) and Chondrocytes (cartilage cells).

3. The "Trade-Off" Map (The Pareto Frontier)

The authors realized that sometimes you can't have everything. Imagine a car: you can have a super-fast car that gets terrible gas mileage, or a slow car that gets amazing mileage. You usually have to choose.

The paper uses a Map of Trade-offs (called a Pareto Frontier) to show this.

• On one side, you have cells that are super easy to program (you can edit their genes easily) but might not last long.
• On the other side, you have cells that last forever but are hard to edit.
• The "Holy Grail" cells are the ones that sit in the top corner of the map: Easy to edit AND last forever. The paper highlights HIP-iPSCs (cells engineered to hide from the immune system) as the current champions sitting in this sweet spot.

4. Why This Matters (The Real-World Impact)

Before this system, choosing a cell for a therapy was like picking a car without knowing its fuel efficiency, safety rating, or engine life. You just hoped for the best.

Now, with the PPS system:

• For Regenerative Medicine: If you need to replace a damaged heart, you look for a cell with a high "Stamina" and "Loyalty" score.
• For Cancer Therapy: If you need to hunt down a tumor, you might pick a cell with a lower "Loyalty" score (because it's okay if it dies after the job is done) but high "Toughness."
• For Drug Testing: If you are testing if a new drug is toxic, you pick a cell that is "fragile" (low resilience) so you can see the damage clearly.

5. The Future: "In Vivo" Programming

The paper also hints at a new frontier: In Vivo Programming.
Imagine instead of building a robot in a factory and shipping it to the construction site, you send a blueprint to the site, and the construction workers build the robot right there.
New technologies are allowing scientists to program cells inside the human body. This changes the game entirely, meaning the "Report Card" might soon need a fifth grade: "Can we program this cell while it's already inside the patient?"

Summary

This paper is essentially a user manual for the human body's building blocks. It gives scientists a standardized way to say, "For this specific job, Cell Type A is a 16/20, while Cell Type B is only a 6/20." It turns the messy, confusing world of cell biology into a clear, data-driven decision-making process, helping us build better cures, safer drugs, and longer-lasting treatments.

Technical Summary

1. Problem Statement

The field of cellular therapies, regenerative medicine, and synthetic biology faces a critical bottleneck: the lack of a quantitative, comparative framework for selecting mammalian cell types.

• Current State: Cell selection is currently "ad hoc," relying on empirical judgment rather than standardized metrics.
• The Gap: With the rapid expansion of candidate cell populations (including engineered populations like hypoimmune iPSCs, CAR-macrophages, and $\gamma\delta$ T cells), researchers lack a unified system to evaluate trade-offs between lifespan, post-transplant persistence, immunogenicity, and chemical resilience.
• Consequence: This absence hinders the rational design of gene therapies, organ-on-chip systems, and immunotherapies, making it difficult to predict which cell types are suitable for long-term applications versus acute assays.

2. Methodology

The authors propose a Systems Framework centered on the Programmability & Persistence Score (PPS), a unified metric ranging from 0 to 20.

A. The PPS Metric

The PPS integrates four biologically relevant traits, each scored from 0 to 5:

1. Intrinsic Stability: Long-term survival capacity (e.g., decades vs. hours).
2. Post-Transplant Persistence: Engraftment durability and functionality after transplantation.
3. Immunogenicity: Inversely scored to reflect immune compatibility (Low immunogenicity = High score).
4. Chemical Resilience: Tolerance to environmental stress and chemical sensitivity.

The score is calculated using a weighted linear model:
$$PPS_{app} = w_{stab} \cdot S_{stab} + w_{persist} \cdot S_{persist} + w_{imm} \cdot S_{imm} + w_{chem} \cdot S_{chem}$$
Weights ($w$) can be adjusted based on the specific application (e.g., cell therapy vs. toxicology screening).

B. Advanced Analytical Extensions

To address the limitations of linear additive scoring (such as compensatory bias and non-linear biological relationships), the framework incorporates:

• Pareto Frontier Analysis: Visualizes multi-objective trade-offs. It identifies "archetype" cell types that are optimal for specific tasks (e.g., neurons for lifespan vs. enterocytes for renewability) and maps engineered cells relative to this frontier.
• Mathematical Alternatives: The authors propose future extensions using Fuzzy Logic (to handle measurement uncertainty, e.g., neutrophil lifespan debates), Bayesian Hierarchical Modeling (for integrating heterogeneous data), and TOPSIS (for ranking based on distance to an ideal solution).

C. Data Synthesis

The framework was applied to a comprehensive dataset of over 50 cell types, including:

• Immune Cells: Neutrophils, Monocytes, Macrophages, T cells (Naïve, Memory, Regulatory, $\gamma\delta$, iNKT), B cells, NK cells.
• Stem Cells: HSCs, NSCs, MSCs, ESCs, iPSCs (including hypoimmune variants).
• Parenchymal Cells: Hepatocytes, Cardiomyocytes, Chondrocytes, Neurons.
• Engineered Populations: CAR-T, CAR-Macrophages, iPSC-derived NK cells, and in vivo generated CAR-T cells.

3. Key Contributions

• Unified Scoring System (PPS): The first composite index (0–20) allowing cross-cell-type comparison across diverse biological domains.
• Integration of Emerging Technologies: The framework explicitly incorporates data from cutting-edge developments, such as hypoimmune engineering (e.g., HIP-iPSCs), in vivo cell programming (e.g., Kelonia's KLN-1010), and new lineage tracing (EPI-Clone, CRISPR barcoding).
• Pareto Optimization Visualization: Shifts the paradigm from simple ranking to multi-objective optimization, revealing that many cell types occupy the "interior" of the trade-off space, indicating room for engineering improvement.
• Standardization for Regulation: Provides a potential basis for regulatory standardization (FDA/EMA) in cell therapy potency assurance and organ-on-chip sourcing.

4. Key Results & Findings

The study categorizes cell types into four tiers based on their PPS:

• High-PPS Tier (15–18): Ideal for Long-Term Regenerative Applications

  • HIP-iPSCs (Score 18): Top performer due to indefinite expandability, immune evasion (B2M/CIITA/CD47 knockouts), and proven clinical efficacy (Sana Biotechnology's UP421).
  • Chondrocytes, Astrocytes, Sertoli Cells, HLA-matched HSCs (Scores 15–16): Exhibit high persistence and low immunogenicity.
  • Engineered Tregs & Microglia (Score 15): High potential for tolerance induction and CNS applications.

• Upper-Mid Tier (12–14): Balanced Trade-offs

  • $\gamma\delta$ T Cells (Score 13): Offer MHC-independent recognition (no GvHD risk) with moderate persistence.
  • CAR-T (4-1BB) & iPSC-NK (Score 12–13): Show improved durability compared to CD28-based CAR-Ts or standard NK cells.
  • Hepatocytes & Memory B Cells (Score 12–14): Moderate persistence but higher immunogenicity or chemical sensitivity.

• Low-PPS Tier (≤9): Acute/Sentinel Applications

  • Neutrophils (Score 8): Short lifespan (19h–5.4d debate) and high chemical sensitivity; suitable for acute assays but not grafts.
  • CAR-Macrophages (Score 9): Limited by inherent myeloid lineage persistence.
  • Enterocytes (Score 4): Extremely short lifespan, high turnover.

Specific Insights:

• Hepatocyte Heterogeneity: Diploid hepatocytes have a significantly higher turnover rate (<3 years) compared to polyploid hepatocytes, necessitating range-based scoring rather than single values.
• Neutrophil Lifespan: The framework accommodates the controversy between conventional labeling (19h) and deuterium labeling (5.4 days) using fuzzy logic concepts.
• Engineering Impact: Engineered populations (orange markers in Figure 2) generally shift toward the "ideal" quadrant (low immunogenicity, high persistence), with HIP-iPSCs approaching the theoretical Pareto optimum.

5. Significance

• Translational Bridge: The PPS framework bridges cell biology with translational engineering, enabling data-driven selection of cell types for specific clinical needs (e.g., choosing HIP-iPSCs for Type 1 Diabetes vs. neutrophils for toxicity screening).
• Future-Proofing: By incorporating mathematical extensions (Pareto, Fuzzy, Bayesian), the framework is adaptable to new data and complex biological non-linearities.
• Regulatory Utility: As the FDA and EMA increase scrutiny on Cell and Gene Therapy (CGT) products, a standardized scoring system offers a pathway for potency assurance and comparative safety assessment.
• AI Integration: The authors suggest that as foundation models (e.g., scGPT, CZI Virtual Cells) mature, PPS sub-scores could eventually be predicted directly from transcriptomic signatures, enabling real-time cell selection optimization for precision medicine.

In conclusion, this paper moves cell selection from an empirical art to a reproducible, design-oriented science, providing a critical tool for the next generation of cellular therapies and synthetic biology applications.